<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00278408</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000459796</org_study_id>
    <secondary_id>DSHNHL-2004-3</secondary_id>
    <secondary_id>EUDRACT-2005-005218-19</secondary_id>
    <secondary_id>EU-205111</secondary_id>
    <nct_id>NCT00278408</nct_id>
  </id_info>
  <brief_title>Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Randomized Study Comparing an Immuno-Chemotherapy With 6 Cycles of the Monoclonal Anti-CD20 Antibody Rituximab in Combination With 6 Cycles of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) at 21-day Intervals or 14-day Intervals, Both With or Without Consolidating Radiotherapy or Large Tumour Masses (≥7.5 cm) and/or Extranodal Involvement in Patients With Aggressive CD20 B-Cell Lymphoma Aged 18 to 60 Years With Age-Adjusted IPI=1 (All) or IPI=0 With a Large Tumour Mass (≥7.5 cm) [UNFOLDER 21/14 Study]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German High-Grade Non-Hodgkin's Lymphoma Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German High-Grade Non-Hodgkin's Lymphoma Study Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
      ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others
      interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy,
      such as cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, work in
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping
      them from dividing. Radiation therapy uses high-energy x-rays to kill cancer cells. Giving
      rituximab and combination chemotherapy together with radiation therapy may kill more cancer
      cells. It is not yet known which schedule of rituximab and combination chemotherapy is more
      effective when given with or without radiation therapy in treating non-Hodgkin's lymphoma.

      PURPOSE: This randomized phase III trial is studying two different schedules of rituximab and
      combination chemotherapy with or without radiation therapy to compare how well they work in
      treating patients with aggressive B-cell non-Hodgkin's lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the time to treatment failure in patients with previously untreated, low-risk,
           aggressive, B-cell non-Hodgkin's lymphoma treated with 2 different schedules of
           immunochemotherapy comprising rituximab, cyclophosphamide, doxorubicin hydrochloride,
           vincristine, and prednisone with vs without radiotherapy.

      Secondary

        -  Compare the time to progression in patients treated with these regimens.

        -  Compare the overall and disease-free/relapse-free survival of patients treated with
           these regimens.

        -  Compare the complete response rate in patients treated with these regimens.

        -  Compare the tumor control in patients treated with these regimens.

        -  Compare the safety of these regimens in these patients.

        -  Compare the pharmacoeconomics of these regimens.

        -  Compare patient adherence to these regimens.

      OUTLINE: This is an open-label, randomized, multicenter study. Patients are stratified
      according to study center, serum lactic dehydrogenase level (≤ upper limit of normal [ULN] vs
      &gt; ULN), disease stage (I or II vs III or IV), ECOG performance status (0-1 vs 2-3), bulky
      disease, and extranodal involvement. Patients with initial bulky disease and/or qualifying
      extranodal involvement are randomized to 1 of 4 treatment arms. Patients with non-bulky
      disease are randomized to treatment arms I or III.

      All patients will be given the option of receiving a 1-week course of pretreatment therapy
      comprising vincristine IV once on day -6 and oral prednisone once daily on days -6 to 0.

        -  Arm I (R-CHOP-21): Patients receive R-CHOP immunochemotherapy comprising rituximab IV,
           cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1 and
           oral prednisone once daily on days 1-5. Treatment repeats every 21 days for up to 6
           courses in the absence of disease progression or unacceptable toxicity.

        -  Arm II (R-CHOP-21 and radiotherapy): Patients receive R-CHOP as in arm I. Treatment
           repeats every 21 days for up to 6 courses in the absence of disease progression or
           unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who
           achieve a complete remission (CR) undergo radiotherapy 5 days a week for approximately
           5½ weeks.

        -  Arm III (R-CHOP-14): Patients receive R-CHOP as in arm I. Patients also receive
           filgrastim (G-CSF) subcutaneously once daily on days 4-13 or until blood counts recover.
           Treatment repeats every 14 days for up to 6 courses in the absence of disease
           progression or unacceptable toxicity.

        -  Arm IV (R-CHOP-14 and radiotherapy): Patients receive R-CHOP as in arm I. Patients also
           receive G-CSF an in arm III. Treatment repeats every 14 days for up to 6 courses in the
           absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the
           last course of R-CHOP, patients who achieve CR undergo radiotherapy as in arm II.

      Patients in all arms undergo restaging of their disease after courses 3 and 6 of R-CHOP.
      Patients with stable disease after 6 courses or disease progression after courses 3 or 6
      proceed to salvage chemotherapy off study. Patients achieving a partial remission or an
      unconfirmed CR after 6 courses undergo additional restaging 4 weeks later. Patients with
      disease progression proceed to salvage chemotherapy off study. Patients who achieve CR after
      6 courses of R-CHOP or have a confirmed CR after the additional restaging undergo
      radiotherapy according to randomization (as above).

      After completion of study treatment, patients are followed periodically for 5 years and then
      annually thereafter.

      PROJECTED ACCRUAL: A total of 1,072 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment failure (TTF) measured from day 1 of course 1 of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy up to 3 years on study with life-long follow-up</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) rate until first relapse</measure>
    <time_frame>through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression rate during treatment</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor control measured from day 1 of course 1 of CHOP therapy (non-tumor related events are censored)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival measured from day 1 of course 1 of CHOP therapy</measure>
    <time_frame>life-long</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival of patients with complete response (CR) or unconfirmed complete response (CRu) following complete immunochemotherapy</measure>
    <time_frame>through study completion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (adverse events, serious adverse events) assessed at 3 months after completion of study treatment</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Consolidating radiotherapy</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">700</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Interventional: 6 R-CHOP-21</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm I (R-CHOP-21): Patients receive R-CHOP immunochemotherapy comprising rituximab IV, cyclophosphamide IV over 15 minutes, doxorubicin IV, and vincristine IV on day 1 and oral prednisone once daily on days 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional: 6 R-CHOP-21 + radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm II (R-CHOP-21 and radiotherapy): Patients receive R-CHOP as in arm I. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve a complete remission (CR) undergo radiotherapy 5 days a week for approximately 5½ weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional: 6 R-CHOP-14</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm III (R-CHOP-14): Patients receive R-CHOP as in arm I. Patients also receive filgrastim (G-CSF) subcutaneously once daily on days 4-13 or until blood counts recover. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional: 6 R-CHOP-14 and radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm IV (R-CHOP-14 and radiotherapy): Patients receive R-CHOP as in arm I. Patients also receive G-CSF an in arm III. Treatment repeats every 14 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-6 weeks after the last course of R-CHOP, patients who achieve CR undergo radiotherapy as in arm II.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>Interventional: 6 R-CHOP-14</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-14 and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <arm_group_label>Interventional: 6 R-CHOP-21</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-21 + radiotherapy</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-14</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-14 and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>Interventional: 6 R-CHOP-21</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-21 + radiotherapy</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-14</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-14 and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <arm_group_label>Interventional: 6 R-CHOP-21</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-21 + radiotherapy</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-14</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-14 and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <arm_group_label>Interventional: 6 R-CHOP-21</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-21 + radiotherapy</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-14</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-14 and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <arm_group_label>Interventional: 6 R-CHOP-21</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-21 + radiotherapy</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-14</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-14 and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Interventional: 6 R-CHOP-21 + radiotherapy</arm_group_label>
    <arm_group_label>Interventional: 6 R-CHOP-14 and radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed aggressive B-cell non-Hodgkin's lymphoma, including the
             following subtypes:

               -  Grade 3 follicular lymphoma

               -  Diffuse B-cell lymphoma, including diffuse large cell lymphoma with the following
                  variants:

                    -  Centroblastic

                    -  Immunoblastic

                    -  Plasmablastic

                    -  Anaplastic large cell

                    -  T-cell-rich B-cell lymphoma

               -  Primary effusion lymphoma

               -  Intravascular B-cell lymphoma

               -  Primary mediastinal B-cell lymphoma

               -  Burkitt's or Burkitt-like lymphoma

               -  Mantle cell lymphoma (blastoid)

               -  Aggressive marginal zone lymphoma (monocytoid)

          -  Previously untreated disease

          -  CD20-positive disease

          -  International prognostic index (IPI) score 0 or 1 (age-adjusted)

               -  Only patients with bulky disease, as defined by largest single or conglomerate
                  tumor ≥ 7.5 cm in diameter, are allowed to have an IPI score of 0

          -  No mucosa-associated lymphoid tissue (MALT) lymphoma

          -  No CNS involvement of lymphoma (intracerebral, meningeal, or intraspinal)

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Platelet count ≥ 100,000/mm³

          -  WBC ≥ 2,500/mm³

          -  No known hypersensitivity to the study medications

          -  No known HIV-positivity

          -  No active hepatitis infection

          -  Not pregnant or lactating

          -  Negative pregnancy test

          -  No other malignancy within the past 5 years except carcinoma in situ or basal cell
             skin cancer

          -  No impaired left ventricular function

          -  No severe cardiac arrhythmias

          -  No other impaired organ function

          -  No other serious disorder

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or radiotherapy

          -  No prior immunosuppressive treatment with cytostatics

          -  No concurrent participation in other treatment studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael G.M. Pfreundschuh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitaetsklinikum des Saarlandes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum St. Marien</name>
      <address>
        <city>Amberg</city>
        <zip>D-92224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>DOH-86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Aurich</name>
      <address>
        <city>Aurich</city>
        <zip>26603</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth</name>
      <address>
        <city>Bayreuth</city>
        <zip>D-95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Campus Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>D-10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite University Hospital - Campus Virchow Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>D-13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franziskus Hospital</name>
      <address>
        <city>Bielefeld</city>
        <zip>D-33615</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta-Kranken-Anstalt gGmbH</name>
      <address>
        <city>Bochum</city>
        <zip>D-44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>D-38114</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>D-28205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Celle</name>
      <address>
        <city>Celle</city>
        <zip>D-29221</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Kuchwald Chemnitz</name>
      <address>
        <city>Chemnitz</city>
        <zip>09113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Fuer Haematologie Internistische Onkologie</name>
      <address>
        <city>Cologne</city>
        <zip>D-50677</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaetsklinik I at the University of Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>D-50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carl - Thiem - Klinkum Cottbus</name>
      <address>
        <city>Cottbus</city>
        <zip>D-03048</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>D-44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virngrund-Klinik Ellwangen</name>
      <address>
        <city>Ellwangen</city>
        <zip>73479</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hans - Susemihl - Krankenhaus</name>
      <address>
        <city>Emden</city>
        <zip>26721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Eschweiler</city>
        <zip>DOH-52249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder) GmbH</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <zip>D-15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der J.W. Goethe Universitaet</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>D-79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Garmisch - Partenkirchen GmbH</name>
      <address>
        <city>Garmisch-Partenkirchen</city>
        <zip>D-82467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Josef Hospital</name>
      <address>
        <city>Gelsenkirchen</city>
        <zip>D-45899</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelm-Anton-Hospital gGmbH, Goch</name>
      <address>
        <city>Goch</city>
        <zip>D-47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>D-37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Fuer Innere Medizin, Hematology/Oncology, Ernst Moritz Armdt Universitaet</name>
      <address>
        <city>Greifswald</city>
        <zip>D-17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien Hospital - Katholisches Krankenhaus Hagen gGmbH</name>
      <address>
        <city>Hagen</city>
        <zip>D-58095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria Halle-Doelau gGmbH</name>
      <address>
        <city>Halle</city>
        <zip>D-06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg - Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stadt Hanau</name>
      <address>
        <city>Hanau</city>
        <zip>63450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Siloah - Medizinische Klinik II</name>
      <address>
        <city>Hannover</city>
        <zip>D-30449</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaetsklinik und Poliklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privatklinik Dr. R. Schindlbeck GmbH &amp; Co. KG</name>
      <address>
        <city>Herrsching</city>
        <zip>D-82211</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bernward Krankenhaus</name>
      <address>
        <city>Hildesheim</city>
        <zip>D-31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematologie und Internistische Onkologie Praxis</name>
      <address>
        <city>Homberg</city>
        <zip>D-34576</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>D-66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic for Bone Marrow Transplantation and Hematology and Oncology</name>
      <address>
        <city>Idar-Oberstein</city>
        <zip>D-55743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Gemeinschaftspraxis - Kassel</name>
      <address>
        <city>Kassel</city>
        <zip>D-34117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kempten Oberallgaeu</name>
      <address>
        <city>Kempten</city>
        <zip>D-87439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtisches Krankenhaus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>23116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein - Kiel Campus</name>
      <address>
        <city>Kiel</city>
        <zip>D-24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Praxis - Landshut</name>
      <address>
        <city>Landshut</city>
        <zip>84028</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen am Rhein</name>
      <address>
        <city>Ludwigshafen am Rhein</city>
        <zip>D-67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus Luedenscheid</name>
      <address>
        <city>Luedenscheid</city>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III Medizinische Klinik Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68305</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>D-32423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Maria Hilf GmbH</name>
      <address>
        <city>Moenchengladbach</city>
        <zip>D-41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematologisch - Onkologische Gemeinschaftspraxis - Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik A - Universitaetsklinikum Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Muenchen - Grosshadern Campus</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerwpunktpraxis Dr. Ladda</name>
      <address>
        <city>Neumarkt</city>
        <zip>D-92318</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>D-26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bruederkrankenhaus St. Josef Paderborn</name>
      <address>
        <city>Paderborn</city>
        <zip>D-33098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>D-93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Suedstadt Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>D-18059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leopoldina - Krankenhaus</name>
      <address>
        <city>Schwienfurt</city>
        <zip>D-97422</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marien - Krankenhaus Siegen GMBH</name>
      <address>
        <city>Siegen</city>
        <zip>D-57072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis - Straubing</name>
      <address>
        <city>Straubing</city>
        <zip>94315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik fuer Onkologie - Katharinenhospital Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>D-70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Mutterhaus der Borromaerinnen</name>
      <address>
        <city>Trier</city>
        <zip>D-54219</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Der Barmherzigen Brueder</name>
      <address>
        <city>Trier</city>
        <zip>D-54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Fuer Internistische Haematologie / Onkologie</name>
      <address>
        <city>Troisdorf</city>
        <zip>53840</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis fuer Haematologie und Onkologie</name>
      <address>
        <city>Twistringen</city>
        <zip>D-27239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Marienhospital - Vechta</name>
      <address>
        <city>Vechta</city>
        <zip>D-49377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hospital Waldbrol</name>
      <address>
        <city>Waldbrol</city>
        <zip>D-51545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst-Schmidt-Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken St. Antonius</name>
      <address>
        <city>Wuppertal 2</city>
        <zip>D-42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinrich-Braun-Krankenhaus Zwickau</name>
      <address>
        <city>Zwickau</city>
        <zip>08060</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - Beilinson Campus</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2006</study_first_submitted>
  <study_first_submitted_qc>January 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2006</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>stage I adult Burkitt lymphoma</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

